(Q33383770)
Statements
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer (English)
C N Sternberg
H Dumez
H Van Poppel
I Skoneczna
A Sella
T Gil
P Carpentier
L Collette
D Lacombe
EORTC Genitourinary Tract Cancer Group
17 March 2009
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference